In a trial for retatrutide, the average study participant lost 17.5 percent of their weight after 24 weeks and 24.2 percent after 48 weeks, Eli Lilly said in a June 26 news release. A placebo and the medication were administered subcutaneously in 338 adults who are overweight with a weight-related condition, not including Type 2 diabetes, or obese.
In comparison, an experimental pill version of Novo Nordisk’s Ozempic resulted in 15.1 percent weight loss in a phase 3 study, and an approved injectable drug for chronic weight management, Wegovy, trimmed the average person’s weight by 12.4 percent.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
